Bayesian models for screening and TB Mobile for target inference with Mycobacterium tuberculosis.

The search for compounds active against Mycobacterium tuberculosis is reliant upon high-throughput screening (HTS) in whole cells. We have used Bayesian machine learning models which can predict anti-tubercular activity to filter an internal library of over 150,000 compounds prior to in vitro testing. We used this to select and test 48 compounds in vitro; 11 were active with MIC values ranging from 0.4 μM to 10.2 μM, giving a high hit rate of 22.9%. Among the hits, we identified several compounds belonging to the same series including five quinolones (including ciprofloxacin), three molecules with long aliphatic linkers and three singletons. This approach represents a rapid method to prioritize compounds for testing that can be used alongside medicinal chemistry insight and other filters to identify active molecules. Such models can significantly increase the hit rate of HTS, above the usual 1% or lower rates seen. In addition, the potential targets for the 11 molecules were predicted using TB Mobile and clustering alongside a set of over 740 molecules with known M. tuberculosis target annotations. These predictions may serve as a mechanism for prioritizing compounds for further optimization.

[1]  Robert Nadon,et al.  Statistical practice in high-throughput screening data analysis , 2006, Nature Biotechnology.

[2]  Sean Ekins,et al.  Combining Cheminformatics Methods and Pathway Analysis to Identify Molecules with Whole-Cell Activity Against Mycobacterium Tuberculosis , 2012, Pharmaceutical Research.

[3]  Ann Thayer TAKING DOWN TB: Even with tools to DIAGNOSE, TREAT, AND PREVENT tuberculosis, the disease remains a significant public health and R&D challenge , 2007 .

[4]  David Rogers,et al.  Cheminformatics analysis and learning in a data pipelining environment , 2006, Molecular Diversity.

[5]  Sean Ekins,et al.  Combining Computational Methods for Hit to Lead Optimization in Mycobacterium Tuberculosis Drug Discovery , 2013, Pharmaceutical Research.

[6]  Hans-Dieter Höltje,et al.  Molecular design of two sterol 14α-demethylase homology models and their interactions with the azole antifungals ketoconazole and bifonazole , 2005, J. Comput. Aided Mol. Des..

[7]  Julie Clark,et al.  Discovery of Novel Antimalarial Compounds Enabled by QSAR-Based Virtual Screening , 2013, J. Chem. Inf. Model..

[8]  Andreas Bender,et al.  Fishing the target of antitubercular compounds: in silico target deconvolution model development and validation. , 2009, Journal of proteome research.

[9]  David Beer,et al.  A High-Throughput Screen To Identify Inhibitors of ATP Homeostasis in Non-replicating Mycobacterium tuberculosis , 2012, ACS chemical biology.

[10]  B Testa,et al.  In silico pharmacology for drug discovery: applications to targets and beyond , 2007, British journal of pharmacology.

[11]  D. Pompliano,et al.  Drugs for bad bugs: confronting the challenges of antibacterial discovery , 2007, Nature Reviews Drug Discovery.

[12]  Noriaki Iwase,et al.  Identification of novel inhibitors of M. tuberculosis growth using whole cell based high-throughput screening. , 2012, ACS chemical biology.

[13]  G. Schneider,et al.  Virtual Screening for Selective Allosteric mGluR1 Antagonists and Structure–Activity Relationship Investigations for Coumarine Derivatives , 2007, ChemMedChem.

[14]  Rebecca Voelker,et al.  MDR-TB has new drug foe after fast-track approval. , 2013, JAMA.

[15]  Gisbert Schneider,et al.  Virtual screening: an endless staircase? , 2010, Nature Reviews Drug Discovery.

[16]  Robert A. Field,et al.  New Small-Molecule Synthetic Antimycobacterials , 2005, Antimicrobial Agents and Chemotherapy.

[17]  Barry A. Bunin,et al.  Chemical Space: Missing Pieces in Cheminformatics , 2010, Pharmaceutical Research.

[18]  T. Parish,et al.  A Dual Read-Out Assay to Evaluate the Potency of Compounds Active against Mycobacterium tuberculosis , 2013, PloS one.

[19]  Sean Ekins,et al.  Using Open Source Computational Tools for Predicting Human Metabolic Stability and Additional Absorption, Distribution, Metabolism, Excretion, and Toxicity Properties , 2010, Drug Metabolism and Disposition.

[20]  David John Adams,et al.  Interaction of azole antifungal antibiotics with cytochrome P-450-dependent 14 alpha-sterol demethylase purified from Candida albicans. , 1990, The Biochemical journal.

[21]  Sean Ekins,et al.  Computational Approaches That Predict Metabolic Intermediate Complex Formation with CYP3A4 (+b5) , 2007, Drug Metabolism and Disposition.

[22]  Hélène Decornez,et al.  Early phase drug discovery: cheminformatics and computational techniques in identifying lead series. , 2012, Bioorganic & medicinal chemistry.

[23]  Sean Ekins,et al.  A collaborative database and computational models for tuberculosis drug discovery. , 2010, Molecular bioSystems.

[24]  B. Munos Lessons from 60 years of pharmaceutical innovation , 2009, Nature Reviews Drug Discovery.

[25]  Alex M. Clark,et al.  TB Mobile: a mobile app for anti-tuberculosis molecules with known targets , 2013, Journal of Cheminformatics.

[26]  Ying Zhang,et al.  The magic bullets and tuberculosis drug targets. , 2005, Annual review of pharmacology and toxicology.

[27]  Philip Prathipati,et al.  Global Bayesian Models for the Prioritization of Antitubercular Agents , 2008, J. Chem. Inf. Model..

[28]  Charles C. Persinger,et al.  How to improve R&D productivity: the pharmaceutical industry's grand challenge , 2010, Nature Reviews Drug Discovery.

[29]  Lynn Rasmussen,et al.  High throughput screening of a library based on kinase inhibitor scaffolds against Mycobacterium tuberculosis H37Rv. , 2012, Tuberculosis.

[30]  D. Rogers,et al.  Using Extended-Connectivity Fingerprints with Laplacian-Modified Bayesian Analysis in High-Throughput Screening Follow-Up , 2005, Journal of biomolecular screening.

[31]  Andreas Bender,et al.  Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..

[32]  Barry A. Bunin,et al.  Bayesian models leveraging bioactivity and cytotoxicity information for drug discovery. , 2013, Chemistry & biology.

[33]  Sean Ekins,et al.  Analysis and hit filtering of a very large library of compounds screened against Mycobacterium tuberculosis. , 2010, Molecular bioSystems.

[34]  Camilla Rodrigues,et al.  Totally drug-resistant tuberculosis in India. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[35]  Sean Ekins,et al.  Validating New Tuberculosis Computational Models with Public Whole Cell Screening Aerobic Activity Datasets , 2011, Pharmaceutical Research.

[36]  Anthony E. Klon,et al.  Improved Naïve Bayesian Modeling of Numerical Data for Absorption, Distribution, Metabolism and Excretion (ADME) Property Prediction , 2006, J. Chem. Inf. Model..

[37]  Eric Arnoult,et al.  The challenge of new drug discovery for tuberculosis , 2011, Nature.

[38]  R. Reynolds,et al.  High Throughput Screening for Inhibitors of Mycobacterium tuberculosis H 37 Rv , 2012 .

[39]  S. Ekins,et al.  In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling , 2007, British journal of pharmacology.

[40]  Vinod Nair,et al.  SQ109 Targets MmpL3, a Membrane Transporter of Trehalose Monomycolate Involved in Mycolic Acid Donation to the Cell Wall Core of Mycobacterium tuberculosis , 2012, Antimicrobial Agents and Chemotherapy.

[41]  Hinrich W. H. Göhlmann,et al.  A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis , 2005, Science.

[42]  John B. O. Mitchell,et al.  Hierarchical virtual screening for the discovery of new molecular scaffolds in antibacterial hit identification , 2012, Journal of The Royal Society Interface.

[43]  Lynn Rasmussen,et al.  Antituberculosis activity of the molecular libraries screening center network library. , 2009, Tuberculosis.

[44]  Sean Ekins,et al.  Computational models for tuberculosis drug discovery. , 2013, Methods in molecular biology.

[45]  Joel S. Freundlich,et al.  Computational databases, pathway and cheminformatics tools for tuberculosis drug discovery. , 2011, Trends in Microbiology.

[46]  James C. Sacchettini,et al.  Drugs versus bugs: in pursuit of the persistent predator Mycobacterium tuberculosis , 2008, Nature Reviews Microbiology.

[47]  A. Bender,et al.  Analysis of Pharmacology Data and the Prediction of Adverse Drug Reactions and Off‐Target Effects from Chemical Structure , 2007, ChemMedChem.

[48]  Lynn Rasmussen,et al.  High-throughput screening for inhibitors of Mycobacterium tuberculosis H37Rv. , 2009, Tuberculosis.

[49]  Takushi Kaneko,et al.  Challenges and opportunities in developing novel drugs for TB. , 2011, Future medicinal chemistry.

[50]  Gisbert Schneider,et al.  Comparative virtual screening and novelty detection for NMDA-GlycineB antagonists , 2009, J. Comput. Aided Mol. Des..

[51]  Sean Ekins,et al.  Enhancing Hit Identification in Mycobacterium tuberculosis Drug Discovery Using Validated Dual-Event Bayesian Models , 2013, PloS one.

[52]  S. Ekins,et al.  Progress in predicting human ADME parameters in silico. , 2000, Journal of pharmacological and toxicological methods.

[53]  Giovanni B Migliori,et al.  The global rise of extensively drug-resistant tuberculosis: is the time to bring back sanatoria now overdue? , 2012, The Lancet.